Arbs drugs
Searched over 200M research papers for "arbs drugs"
Summary
10 papers analyzed
Some studies suggest ARBs are associated with a modestly increased risk of new cancer diagnosis, particularly lung cancer, while other studies show no increased risk of cancer or cancer-related mortality compared to placebo.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Angiotensin Receptor Blockers (ARBs): Efficacy, Risks, and Clinical Implications
Introduction to ARBs in Hypertension and Cardiovascular Disease
Angiotensin receptor blockers (ARBs) are a class of medications widely used to manage hypertension, heart failure, and diabetic nephropathy. They function by blocking the angiotensin II type-1 receptor, which plays a crucial role in blood pressure regulation and cardiovascular health .
ARBs and Cancer Risk
Meta-Analysis Findings
Recent meta-analyses have explored the potential link between ARBs and cancer risk. One study involving 61,590 patients found a modestly increased risk of new cancer diagnoses among those treated with ARBs compared to control groups (7.2% vs. 6.0%, risk ratio [RR] 1.08). Specifically, the risk of lung cancer was significantly higher in patients receiving ARBs (0.9% vs. 0.7%, RR 1.25). However, another comprehensive analysis of 324,168 participants found no significant increase in cancer risk with ARBs when compared to other antihypertensive drugs or placebo. This discrepancy highlights the need for further research to clarify the cancer risk associated with ARBs.
ARBs and Renal Outcomes
Renoprotective Effects
ARBs are known for their renoprotective effects, particularly in patients with hypertension and renal disease. Studies have shown that ARBs can reduce proteinuria and delay the progression of renal disease, similar to angiotensin-converting enzyme (ACE) inhibitors . However, the benefits observed in placebo-controlled trials may primarily result from blood pressure reduction rather than intrinsic renoprotective properties.
ARBs and COVID-19
Impact on COVID-19 Severity and Mortality
The COVID-19 pandemic raised concerns about the safety of ARBs, given their interaction with the renin-angiotensin system. Meta-analyses of observational studies have shown that ARBs do not increase the risk of severe or lethal COVID-19. In fact, patients on ARBs had similar or even lower risks of severe outcomes compared to those not on these medications . These findings support the continued use of ARBs during the pandemic, as recommended by several scientific societies .
ARBs and Myocardial Infarction Risk
Cardiovascular Safety
The safety of ARBs concerning myocardial infarction (MI) has been debated. A meta-analysis of randomized clinical trials found no significant increase in MI risk with ARBs compared to placebo or other antihypertensive drugs. This suggests that ARBs are a safe option for patients at risk of cardiovascular events.
Blood Pressure Lowering Efficacy
Comparative Efficacy
ARBs are effective in lowering blood pressure, with no significant differences in efficacy among the various ARBs available. The blood pressure reduction achieved with ARBs is comparable to that of ACE inhibitors, making them a viable option for managing hypertension.
Conclusion
ARBs are a critical component in the management of hypertension, heart failure, and renal disease. While there is some evidence suggesting a modest increase in cancer risk, particularly lung cancer, other studies have not confirmed this association. ARBs are effective in reducing proteinuria and delaying renal disease progression, primarily through blood pressure reduction. Importantly, ARBs do not increase the risk of severe COVID-19 or myocardial infarction, supporting their continued use in clinical practice. Further research is needed to fully understand the long-term risks and benefits of ARBs, particularly concerning cancer.
Sources and full results
Most relevant research papers on this topic
